Cisplatin-DNA Damage Recognition Proteins in Human Tumour Extracts
Author Information
Author(s): D. Bissett, K. McLaughlin, L.R. Kelland, R. Brown
Primary Institution: CRC Department of Medical Oncology, Glasgow; Institute of Cancer Research, Drug Development Section, Surrey, UK.
Hypothesis
Enhanced repair of DNA adducts may be a cause of cisplatin resistance in solid malignancies.
Conclusion
The study identified damage recognition proteins in human ovarian carcinoma cell lines, but no correlation was found between these proteins and cellular sensitivity to cisplatin.
Supporting Evidence
- Enhanced repair of CDDP-DNA adducts is suggested to be an important factor in CDDP resistance.
- Damage recognition proteins were identified in extracts from human ovarian, cervical, and testicular malignancies.
- An increase in binding of damage recognition proteins was observed in a CDDP-resistant ovarian carcinoma cell line compared to its parental line.
Takeaway
Scientists looked at how certain proteins in cancer cells recognize and repair damage caused by a cancer drug called cisplatin, but they found that having more of these proteins didn't always mean the cells were more resistant to the drug.
Methodology
The study used gel mobility shift assays and southwestern blot assays to identify proteins that bind to CDDP-modified DNA in human ovarian carcinoma cell lines and biopsies.
Limitations
There was no correlation between the amount of damage recognition protein and the cellular sensitivity to CDDP, and the functional role of these proteins remains to be established.
Participant Demographics
The study involved human ovarian carcinoma cell lines and biopsies from ovarian, cervical, and testicular malignancies.
Want to read the original?
Access the complete publication on the publisher's website